ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,682,231 | +202.4% | 234,256 | +171.5% | 0.00% | – |
| Q2 2023 | $886,958 | +70.8% | 86,280 | +28.3% | 0.00% | – |
| Q1 2023 | $519,294 | +9.5% | 67,266 | +4.3% | 0.00% | – |
| Q4 2022 | $474,046 | +65.2% | 64,496 | +62.0% | 0.00% | – |
| Q3 2022 | $287,000 | -15.3% | 39,823 | 0.0% | 0.00% | – |
| Q2 2022 | $339,000 | +16.5% | 39,823 | +22.8% | 0.00% | – |
| Q1 2022 | $291,000 | -30.4% | 32,417 | +7.6% | 0.00% | – |
| Q4 2021 | $418,000 | +58.9% | 30,123 | +22.3% | 0.00% | – |
| Q3 2021 | $263,000 | +1.5% | 24,623 | -14.4% | 0.00% | – |
| Q2 2021 | $259,000 | – | 28,760 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 4,708,288 | $42,233,000 | 12.94% |
| Lynx1 Capital Management LP | 1,484,693 | $13,318,000 | 12.36% |
| Omega Fund Management, LLC | 2,029,580 | $18,205,000 | 3.73% |
| TCG Crossover Management, LLC | 1,034,222 | $9,277,000 | 3.72% |
| Frazier Life Sciences Management, L.P. | 4,185,757 | $37,546,000 | 3.20% |
| Paradigm Biocapital Advisors LP | 336,229 | $3,016,000 | 0.80% |
| Orbimed Advisors | 4,081,592 | $36,612,000 | 0.59% |
| BVF INC/IL | 1,589,495 | $14,258,000 | 0.57% |
| Kingsbury Capital Investment Advisors LLC | 29,153 | $262,000 | 0.29% |
| Avidity Partners Management LP | 1,207,000 | $10,827,000 | 0.22% |